FACS-Positive Antibody Discovery Service

Overview FACS Antibodies High-throughput FACS Significance Published Data Key Features

Overview of Fluorescence-Activated Cell Sorting (FACS)

FACS is a particular type of flow cytometry that highly relies on antibodies labeled with fluorescent conjugates. In addition to simultaneously collecting multiple data on biological samples, FACS can also classify biological samples by different parameters. Importantly, FACS is capable of rapidly recording the fluorescence signals of single cells, as well as effectively isolating desired cells. Thus, FACS has proved to be a useful tool for studying the cellular basis of health and disease. Currently, FACS also plays a crucial role in FACS-positive hybridoma screening.

FACS Antibodies

FACS antibodies are key media for flow cytometry detection. In general, fluorescently conjugated antibodies are suitable for direct detection while unconjugated antibodies are suitable for indirect detection. The quality of the antibody is decisive for flow cytometry detection. Antibodies used in FACS play a crucial role in detecting low-abundance markers. Furthermore, FACS contributes to determining the efficiency of specific treatments, which greatly facilitates the development of targeted or personalized treatments.

Fig.1 Outline of FACS procedures. (He, et al., 2015) Fig.1 Procedures for FACS analysis of heterotypic CICs.^{1, 3}

High-throughput FACS Technology

Although screening available hybridomas is a complex and arduous task, the emergence of various high-throughput technologies has provided new opportunities for screening target hybridomas. FACS technology represents an attractive high-throughput technology for in vitro screening of positive hybridomas. Creative has developed an advanced High-throughput FACS Hybridoma Screening Platform. Within this platform, we can screen hundreds of candidate clones with high speed and high sensitivity. To obtain FACS-positive hybridoma clones, usually we perform the high-throughput FACS screening from the specific screening of clones, and specific screening of sub-clones, to the final verification of antibodies. Our experts with years of screening experience will give you the best screening solution to promote your project to success.

Fig.2 High-throughput FACS Technology. (Creative Biolabs Original) Fig.2 Specific screening of hybridoma clones by FACS.

Why Perform FACS Verification?

FACS is a robust and well-established method for antibody validation.
FACS has a strong track record of cost-effectively screening high-quality antibodies.
FACS effectively verifies antibodies of higher stability.

Published Data

CellectAb antibody screening strategies. Fig.3 CellectAb antibody screening methodology and antigen identifcation.^{2, 3}

Cell surface antigen discovery captivates the interest of biomedical researchers, particularly when it comes to isolating rare cell populations and therapeutic targeting. Nixon, Allison ML, et al. utilized AC133 cell populations to screen for potential markers of colorectal cancer-initiating cells (CICs).^2,3 Their objective was to merge unbiased target and antibody discovery with a functional subset of cancer cells, with the ultimate goal of identifying antibodies that could label and potentially treat these cells. They utilized a colorectal cancer (CRC) spheroid model that preserves cellular heterogeneity and stem-like characteristics. By utilizing the AC133 epitope, they enriched for functional CICs. To segregate the CIC population, the spheroids were initially broken down into a suspension of individual cells and then labeled with AC133. Subsequently, they employed FACS to separate the cells into two populations: CD133-high presumptive CICs and a CD133-low bulk cell population. During the antibody selection process, they used live cells to generate antibodies against native antigens. Over an eight-hour period and under controlled low flow pressure conditions, they successfully isolated cells using FACS.

Features of Our Services

High specificity

Our team is an expert in hybridoma screening, resulting in a final product that is highly specific for your FACS experiments.

Optimal Results

Our validated FACS hybridoma screening strategy significantly improves the feasibility of antibodies for FACS applications.

Fast turnaround time

We can complete FACS-positive hybridoma screening in a shorter time with a complete experimental report.

Creative Biolabs has been committed to providing suitable hybridoma development services to customers in more than 30 countries and regions around the world. Based on our rich experience and expertise in hybridoma antibody production, we are willing to provide you with a cost-effective FACS-positive hybridoma screening service. If you are looking for custom antibodies for FACS use, please contact us for more details about customization services.

References

He, Meifang, et al. "Fluorescence-activated cell sorting analysis of heterotypic cell-in-cell structures." Scientific Reports 5.1 (2015): 9588.
Nixon, Allison ML, et al. "A rapid in vitro methodology for simultaneous target discovery and antibody generation against functional cell subpopulations." Scientific reports 9.1 (2019): 842.
Distributed under Open Access license CC BY 4.0, without modification.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: